Randomized control trials (RCTs) have shown that certain intravenous iron preparations can induce high levels of fibroblast growth factor 23 (FGF-23) and persistent hypophosphatemia. Repeated iron infusions may lead to prolonged hypophosphatemia and osteomalacia events not captured by RCTs. Several previous case reports have described skeletal adverse effects after repeated iron infusions. To characterize these effects, we conducted a systematic review of case reports. MEDLINE, Embase, Web of Science, and Cochrane databases were searched in March 2021. We selected case reports of patients ≥16 years old. Study quality was assessed using the tool from Murad and colleagues. We report the results in a narrative summary. We identified 28 case re...
Ferric carboxymaltose (FCM) and iron isomaltoside 1000 (IIM) are increasingly used because they allo...
Ferric carboxymaltose (FCM) has been shown to achieve rapid replenishment of iron stores and correct...
Introduction Rare FGF23-producing mesenchymal tumors lead to paraneoplastic tumor-induced osteomalac...
This case report describes a 65-year-old man with a Rendu-Osler-Weber syndrome with secondary chroni...
Iron-induced hypophosphataemic osteomalacia remains under-recognized as a potential complication of ...
Iron-induced hypophosphataemic osteomalacia remains under-recognized as a potential complication of ...
Key Clinical Message Hypophosphatemia postintravenous iron is frequent but under-recognized. If prol...
Iron isomaltoside (IIM) and ferric carboxymaltose (FCM) are newer intravenous iron preparations that...
Ferric carboxymaltose (FCM) is a novel iron formulation increasingly prescribed due to its effective...
A post-menopausal patient with normal kidney function was referred to our hospital because of severe...
Some, but not all, intravenous iron formulations have been recognized to induce renal phosphate wast...
A post-menopausal patient with normal kidney function was referred to our hospital because of severe...
<div><p>Background</p><p>Ferric carboxymaltose (FCM) and iron isomaltoside 1000 (IIM) are increasing...
Background: Iron deficiency is the most common global cause of anaemia. Intravenous (IV) iron is us...
Iron deficiency is common and can be effectively treated with parenteral iron infusion. We report a ...
Ferric carboxymaltose (FCM) and iron isomaltoside 1000 (IIM) are increasingly used because they allo...
Ferric carboxymaltose (FCM) has been shown to achieve rapid replenishment of iron stores and correct...
Introduction Rare FGF23-producing mesenchymal tumors lead to paraneoplastic tumor-induced osteomalac...
This case report describes a 65-year-old man with a Rendu-Osler-Weber syndrome with secondary chroni...
Iron-induced hypophosphataemic osteomalacia remains under-recognized as a potential complication of ...
Iron-induced hypophosphataemic osteomalacia remains under-recognized as a potential complication of ...
Key Clinical Message Hypophosphatemia postintravenous iron is frequent but under-recognized. If prol...
Iron isomaltoside (IIM) and ferric carboxymaltose (FCM) are newer intravenous iron preparations that...
Ferric carboxymaltose (FCM) is a novel iron formulation increasingly prescribed due to its effective...
A post-menopausal patient with normal kidney function was referred to our hospital because of severe...
Some, but not all, intravenous iron formulations have been recognized to induce renal phosphate wast...
A post-menopausal patient with normal kidney function was referred to our hospital because of severe...
<div><p>Background</p><p>Ferric carboxymaltose (FCM) and iron isomaltoside 1000 (IIM) are increasing...
Background: Iron deficiency is the most common global cause of anaemia. Intravenous (IV) iron is us...
Iron deficiency is common and can be effectively treated with parenteral iron infusion. We report a ...
Ferric carboxymaltose (FCM) and iron isomaltoside 1000 (IIM) are increasingly used because they allo...
Ferric carboxymaltose (FCM) has been shown to achieve rapid replenishment of iron stores and correct...
Introduction Rare FGF23-producing mesenchymal tumors lead to paraneoplastic tumor-induced osteomalac...